Winning Trust Through Mabion Biologics CDMO Excellence
- CDMO Leadership Awards for Mabion underscore its strength in biologic drug development, analytics, and commercial manufacturing.
- The company’s presence at DCAT Week 2025 reflects its growing role as an international CDMO for biologics.
- In a dynamic week of industry engagement, Marty Henehan reflects on how the value of customer dialogue and strategic alignment drive long-term partnerships and value creation.
- With bold plans for growth, Mabion is focused on scaling its capabilities and delivering turnkey biologics solutions.
Fresh from a week of high-level networking at DCAT Week in New York, Marty Henehan, VP of Business Development – Head of North America at Mabion recounts how participation in such global industry trade shows helps solidify Mabion’s position as a competitive international CDMO for biologics. His insights provide a clear picture of a CDMO focused on reliability, responsiveness and long-term value.
Q: An intensive week has just ended, during which Mabion representatives conducted networking at BIO-Europe Spring in Milan and DCAT Week in New York. You participated in the US event. How does participating in global events like DCAT strengthen Mabion’s position as an International CDMO for Biologics?
Marty Henehan (MH): The pharmaceutical and biologics industry has always placed high value on in-person interactions between service providers and sponsors. Given the collaborative nature of this business, close communication throughout the development process is essential. Attending events like DCAT and BIO-Europe enables our Mabion team to reconnect with current and former clients, while also providing a great opportunity to meet potential new partners and share insights into how we can bring value to their projects.
Q: What have been the most valuable discussions or partnerships Mabion has engaged in at DCAT Week 2025?
MH: It’s difficult to highlight a single area or partnership as the most valuable, as each interaction brings unique insights. Meeting with our current clients is always a priority, as it allows us to gather valuable feedback and ensure we are not only meeting but exceeding expectations. At the same time, we are continuously evaluating market needs and exploring strategic collaborations with other service providers. Our goal is to bridge any service gaps and deliver comprehensive, turn-key solutions for our sponsors.
Mabion – Champion of International Biologics CDMO Leadership Awards 2025
Q: Mabion was crowned Champion in the International Biologics category at the 2025 CDMO Leadership Awards ceremony. What does winning the 2025 International CDMO Leadership Award in Biologics mean for Mabion?
MH: Being recognized by both the industry and our clients is a tremendous honor. Being named International Champion is a powerful validation of our client-centric approach and the value it brings. It’s also a fantastic reflection of the exceptional talent and dedication of the entire Mabion team.
Q: What key strengths and innovations helped Mabion secure this recognition? What are some of Mabion’s most significant achievements in biologic drug development and manufacturing over the past year?
MH: Over the past year, Mabion’s recognition has been driven by a combination of key strengths and forward-looking innovations. One of our most important assets is our deep expertise in biologic drug development – especially in the areas of process optimization, technology transfer, and scale-up under GMP conditions. Our team has consistently demonstrated the ability to deliver high-quality results efficiently, which builds confidence with partners and clients alike.
Another major strength is our flexibility and responsiveness as a CDMO. We’ve positioned ourselves as a collaborative partner, offering tailored solutions across the biologics development lifecycle – from early-stage development to commercial-scale manufacturing. This adaptability has been crucial in meeting evolving client needs and timelines.
In terms of innovation, we’ve made meaningful investments in modernizing our facility and improving our analytical capabilities, which has expanded our service offerings. We’ve also implemented more digital tools and data-driven decision-making in process development and quality control, improving both speed and reliability.
Among our most significant achievements this past year is the successful execution of multiple tech transfer projects for international clients, with timelines met or exceeded. We’ve also strengthened our position in the global supply chain for biologics by deepening existing partnerships and entering new strategic collaborations.
Together, these accomplishments reflect not only technical excellence but also a mindset of continuous improvement and client-centric innovation.
Q: The development of biopharma needs is very dynamic. Previously unmet therapeutic targets are receiving pioneering therapies. How does Mabion plan to stay at the forefront of the evolving biological sector?
MH: While the industry continues to evolve with new therapies and increasing demands, at Mabion we remain focused on our core strength: mammalian cell culture projects. We are actively investing in advanced technologies to enhance our service offerings, improve efficiency, and support strong regulatory outcomes. Additionally, we are developing plans to expand our existing manufacturing facility, which will enable greater scale and broaden the range of services we provide.
Thanks to Marty for granting the interview and providing detailed insights on Mabion’s CDMO Excellence for Biologics. For more information about Mabion’s capabilities as an International CDMO, check out our services for biologics.
Biography
Marty Henehan serves as the Vice President of Business Development and Head of North America at Mabion S.A., a leading European CDMO specializing in biologics. With an extensive experience in sales management, CMC and business development, Marty has a proven track record of driving growth and fostering strategic partnerships within the biopharma industry.
His focus on building strong client relationships and understanding market dynamics has enabled Mabion to provide tailored solutions that meet the diverse needs of biopharma clients worldwide. Marty’s efforts and expertise have been instrumental in enhancing Mabion’s reputation as a trusted partner in the biopharmaceutical industry, particularly in North America.
Prepared by:
Sources and further reading
- 2025 CDMO Leadership Awards photo gallery
- Bartusik-Czubek E, Bednarek M, Jaros D. 4 Critical Strategies For Successful Biologic Drug Development. Outsourced Pharma, 2025.
- Mabion announced as CDMO Leadership Awards Champion during DCAT Week
- Mabion is a Champion of the 2025 International CDMO Leadership Award in Biologics